Merck Revises Guidance To Include $700 Million Less In Vytorin/Zetia Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Company, however, reaffirms EPS guidance for the year.
You may also be interested in...
Lipitor Study Creates More Doubts On CRP Study Used To Expand Crestor Label
A new analysis of a large European trial presented at the American Heart Association annual meeting has further damaged the case for using C-reactive protein levels as a guide for statin therapy.
Lipitor Study Creates More Doubts On CRP Study Used To Expand Crestor Label
A new analysis of a large European trial presented at the American Heart Association annual meeting has further damaged the case for using C-reactive protein levels as a guide for statin therapy.
Merck Outlines Plans For 2009 NDA Filings; Migraine Drug Is Best Bet
Merck's fledgling bioventures business may have dominated headlines following the company's recent analyst day, but the firm's other initiatives are likely to contribute more to near-term growth as Merck tries to address the revenue gap that will be left by key patent expirations in the next few years